In vivo, xenograft assays confirmed that IGF2BP2 knockdown significantly inhibited tumor growth, with CBP further enhancing this effect (Figure 3L–N; Figure S5I, Supporting Information). The gene discussed is IGF2BP2; the disease is neoplasm.